The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
But PFS data are lacking, and there are questions about first and second-line plans.
Three private biotechs enter clinical trials, one targeting KRAS.
But the company still has a lot to prove with ERAS-0015.
